阿尔茨海默病及相关痴呆症在研究、诊断和治疗方面的挑战与进展。
Challenges and progress in research, diagnostics, and therapeutics in Alzheimer's disease and related dementias.
作者信息
Dokholyan Nikolay V, Mohs Richard C, Bateman Randall J
机构信息
Departments of Pharmacology Penn State College of Medicine Hershey Pennsylvania USA.
Departments of Biochemistry & Molecular Biology Penn State College of Medicine Hershey Pennsylvania USA.
出版信息
Alzheimers Dement (N Y). 2022 Jul 26;8(1):e12330. doi: 10.1002/trc2.12330. eCollection 2022.
Abstract
The health, well-being, and financial security of Americans are greatly impacted by Alzheimer's disease. The forecast paints an upward trajectory with the number of Americans suffering from Alzheimer's disease and related dementia. To discuss the Alzheimer's crisis, The Senate Committee on Finance, Subcommittee on Health Care, held a hearing titled, "The Alzheimer's Crisis: Examining, Testing, and Treatment Pipelines and Fiscal Implications," on December 16, 2020. Here, we summarize and expand on the discussion of the panel and its review of recent progress, ongoing challenges associated with Alzheimer's disease, and potential initiatives that promise to speed progress in developing treatments and improving care.
摘要
阿尔茨海默病对美国人的健康、福祉和金融安全产生了巨大影响。预测显示，患有阿尔茨海默病及相关痴呆症的美国人数量呈上升趋势。为讨论阿尔茨海默病危机，参议院金融委员会医疗保健小组委员会于2020年12月16日举行了一场题为“阿尔茨海默病危机：审视、测试及治疗流程与财政影响”的听证会。在此，我们总结并详述了专家小组的讨论内容，以及其对近期进展、与阿尔茨海默病相关的持续挑战，以及有望加快治疗研发进程和改善护理的潜在举措的审查情况。
相似文献
1
Challenges and progress in research, diagnostics, and therapeutics in Alzheimer's disease and related dementias.
Alzheimers Dement (N Y). 2022 Jul 26;8(1):e12330. doi: 10.1002/trc2.12330. eCollection 2022.
2
Alzheimer's Disease-Related Dementias Summit 2022: National Research Priorities for the Investigation of Post-Traumatic Brain Injury Alzheimer's Disease and Related Dementias.
J Neurotrauma. 2023 Aug;40(15-16):1512-1523. doi: 10.1089/neu.2022.0514. Epub 2023 Apr 25.
3
Alzheimer's Disease-Related Dementias Summit 2019: National Research Priorities for the Investigation of Traumatic Brain Injury as a Risk Factor for Alzheimer's Disease and Related Dementias.
J Neurotrauma. 2021 Dec;38(23):3186-3194. doi: 10.1089/neu.2021.0216.
4
Neurovascular Dysfunction in Diverse Communities With Health Disparities-Contributions to Dementia and Alzheimer's Disease.
Front Neurosci. 2022 Jun 29;16:915405. doi: 10.3389/fnins.2022.915405. eCollection 2022.
5
Alzheimer's disease and Alzheimer's disease-related dementias in Hispanics: Identifying influential factors and supporting caregivers.
Ageing Res Rev. 2024 Jan;93:102178. doi: 10.1016/j.arr.2023.102178. Epub 2023 Dec 27.
6
Engaging Stakeholders in the Design and Conduct of Embedded Pragmatic Clinical Trials for Alzheimer's Disease and Alzheimer's Disease-Related Dementias.
J Am Geriatr Soc. 2020 Jul;68 Suppl 2(Suppl 2):S62-S67. doi: 10.1111/jgs.16630.
7
2021 Alzheimer's disease facts and figures.
Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23.
8
The effectiveness of exercise interventions targeting sleep in older adults with cognitive impairment or Alzheimer's disease and related dementias (AD/ADRD): A systematic review and meta-analysis.
J Sleep Res. 2024 Dec;33(6):e14189. doi: 10.1111/jsr.14189. Epub 2024 Mar 10.
9
New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop.
Alzheimers Dement (N Y). 2024 Mar 10;10(1):e12458. doi: 10.1002/trc2.12458. eCollection 2024 Jan-Mar.
10
Sex and gender considerations in Alzheimer's disease: The Women's Brain Project contribution.
Front Aging Neurosci. 2023 Mar 30;15:1105620. doi: 10.3389/fnagi.2023.1105620. eCollection 2023.
引用本文的文献
1
High-fidelity and differential nonsense suppression in live cells and a frontotemporal dementia allele with human transfer RNAs.
Nucleic Acids Res. 2025 Jul 19;53(14). doi: 10.1093/nar/gkaf730.
2
Amyloid-β plaque-associated microglia drive TSPO upregulation in Alzheimer's disease.
Acta Neuropathol. 2025 Jul 17;150(1):6. doi: 10.1007/s00401-025-02912-4.
3
Co-Aggregation of Syndecan-3 with β-Amyloid Aggravates Neuroinflammation and Cognitive Impairment in 5×FAD Mice.
Int J Mol Sci. 2025 Jun 8;26(12):5502. doi: 10.3390/ijms26125502.
4
Multi-Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations.
Pharmacol Res Perspect. 2025 Aug;13(4):e70131. doi: 10.1002/prp2.70131.
5
Alzheimer's subtypes A supervised, unsupervised, multimodal, multilayered embedded recursive (SUMMER) AI study.
bioRxiv. 2025 May 14:2025.05.09.653177. doi: 10.1101/2025.05.09.653177.
6
Neuroprotective Properties of Clove (): State of the Art and Future Pharmaceutical Applications for Alzheimer's Disease.
Biomolecules. 2025 Mar 20;15(3):452. doi: 10.3390/biom15030452.
7
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer's Disease.
Mol Neurobiol. 2025 Mar 25. doi: 10.1007/s12035-025-04838-0.
8
QuICSeedR: an R package for analyzing fluorophore-assisted seed amplification assay data.
Bioinformatics. 2024 Dec 26;41(1). doi: 10.1093/bioinformatics/btae752.
9
Prevalence of Unrecognized Cognitive Impairment in Federally Qualified Health Centers.
JAMA Netw Open. 2024 Oct 1;7(10):e2440411. doi: 10.1001/jamanetworkopen.2024.40411.
10
Ras, RhoA, and vascular pharmacology in neurodevelopment and aging.
Neurochem Int. 2024 Dec;181:105883. doi: 10.1016/j.neuint.2024.105883. Epub 2024 Oct 18.
本文引用的文献
1
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.
2
Value-Generating Exploratory Trials in Neurodegenerative Dementias.
Neurology. 2021 May 18;96(20):944-954. doi: 10.1212/WNL.0000000000011774. Epub 2021 Mar 5.
3
Transition from physical to virtual visit format for a longitudinal brain aging study, in response to the Covid-19 pandemic. Operationalizing adaptive methods and challenges.
Alzheimers Dement (N Y). 2020 Aug 27;6(1):e12055. doi: 10.1002/trc2.12055. eCollection 2020.
4
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
JAMA. 2020 Aug 25;324(8):772-781. doi: 10.1001/jama.2020.12134.
5
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.
Nat Med. 2020 Mar;26(3):398-407. doi: 10.1038/s41591-020-0781-z. Epub 2020 Mar 11.
6
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1.
7
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.
8
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.
Alzheimers Dement. 2017 Aug;13(8):841-849. doi: 10.1016/j.jalz.2017.06.2266. Epub 2017 Jul 19.
9
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.
Alzheimers Dement. 2017 Jan;13(1):8-19. doi: 10.1016/j.jalz.2016.07.005. Epub 2016 Aug 29.
10
Alzheimer's disease: the amyloid cascade hypothesis.
Science. 1992 Apr 10;256(5054):184-5. doi: 10.1126/science.1566067.
Zotero 插件